SCHEMBL296765

SCHEMBL296765

CNc1nc(-c2cccc(NC(=O)c3ccccc3)c2)c2cc(OC)c(OC)cc2n1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.85
PDE4B Q07343 1/20 0.85
PDE4C Q08493 1/20 0.85
PDE4D Q08499 1/20 0.85
MAPK14 Q16539 3/20 0.54
EGFR P00533 2/20 0.54
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
POLB P06746 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
TSHR P16473 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
KCNK9 Q9NPC2 3/20 0.49
KCNK3 O14649 2/20 0.49
ADORA3 P0DMS8 1/20 0.49
WHR1 P49842 1/20 0.49
AURKA O14965 1/20 0.48
AURKB Q96GD4 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296279 0.94 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DMAPK14
SCHEMBL1942916 0.94 PDE4A (0.76) PDE4APDE4BPDE4CPDE4DMAPK14
Hydrochloric Acid SCHEMBL296658 0.93 PDE4A (0.84) PDE4APDE4BPDE4CPDE4DMAPK14
SCHEMBL371380 0.93 PDE4A (0.78) PDE4APDE4BPDE4CPDE4DMAPK14
SCHEMBL6778879 0.93 PDE4A (0.75) PDE4APDE4BPDE4CPDE4DMAPK14
SCHEMBL297387 0.93 PDE4A (0.87) PDE4APDE4BPDE4CPDE4DMAPK14
SCHEMBL1942703 0.92 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL296482 0.92 PDE4A (0.79) PDE4APDE4BPDE4CPDE4DMAPK14
SCHEMBL1941692 0.92 PDE4A (0.82) PDE4APDE4BPDE4CPDE4DMAPK14
Lotamilast SCHEMBL369445 0.92 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348311-A1 TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE Dermavant Sciences GmbH (CH) 2017-12-07 US disclosed
US-8530654-B2 Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-09-10 US disclosed
US-8530654-B2 Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-09-10 US disclosed
US-8513269-B2 Preparation for external use EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-08-20 US disclosed
US-8513269-B2 Preparation for external use EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-08-20 US disclosed
US-8513269-B2 Preparation for external use EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-08-20 US disclosed
US-8492543-B2 Method for producing quinazoline derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-07-23 US disclosed
EP-2202229-B1 NOVEL PREPARATION FOR EXTERNAL USE EISAI R&D MAN CO LTD (JP) 2012-03-14 EP disclosed
CN-101389612-B Quinazoline derivatives EISAI R&D MAN CO LTD 2011-09-21 CN disclosed
EP-1992622-B1 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2011-07-27 EP disclosed
US-20080187978-A1 Anti-inflammatory medicaments FLYNN DANIEL L 2008-08-07 US disclosed
US-20070299094-A1 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives EISAI R&D MANAGEMENT CO., LTD. 2007-12-27 US disclosed
US-20070299094-A1 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives EISAI R&D MANAGEMENT CO., LTD. 2007-12-27 US disclosed
US-20070299094-A1 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives EISAI R&D MANAGEMENT CO., LTD. 2007-12-27 US disclosed
US-20070299094-A1 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives EISAI R&D MANAGEMENT CO., LTD. 2007-12-27 US disclosed
WO-2007097317-A1 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE EISAI R & D MANAGEMENT CO., LTD. (JP) 2007-08-30 WO disclosed
US-6800644-B2 PHOSPHODIESTERASE-4 INHIBITOR, AMINOQUINOLINE OR AMINOISOQUINOLINE DERIVATIVES EISAI CO., LTD. (JP) 2004-10-05 US disclosed
US-20020055516-A1 Nitrogen-containing heterocyclic compounds and medicaments containing the compounds EISAI CO., LTD. 2002-05-09 US disclosed
US-6352989-B1 ENZYME INHIBITORS FOR PHOSPHODIESTERASE EISAI CO., LTD. (JP) 2002-03-05 US disclosed
EP-1052254-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF Eisai Co., Ltd. (JP) 2000-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055516-A1 Nitrogen-containing heterocyclic compounds and medicaments containing the compounds PDE4A, PDE4B, PDE5A PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885
US-20070299094-A1 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives ITCH, HRH4, HRH1 PDE4A 1280/4885PDE4B 1378/4885PDE4C 2057/4885
US-20170348311-A1 TOPICAL FORMULATIONS OF PDE-4 INHIBITORS AND THEIR METHODS OF USE PDE4A, PDE4B, PDE4C PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.